JP7110232B2 - フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 - Google Patents

フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 Download PDF

Info

Publication number
JP7110232B2
JP7110232B2 JP2019556703A JP2019556703A JP7110232B2 JP 7110232 B2 JP7110232 B2 JP 7110232B2 JP 2019556703 A JP2019556703 A JP 2019556703A JP 2019556703 A JP2019556703 A JP 2019556703A JP 7110232 B2 JP7110232 B2 JP 7110232B2
Authority
JP
Japan
Prior art keywords
methyl
amino
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517555A (ja
Inventor
マルタ マリア シフエンテス－ガルシア，
マリア クリスティナ ガルシア－パレデス，
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2021517555A publication Critical patent/JP2021517555A/ja
Priority to JP2022115300A priority Critical patent/JP7331212B2/ja
Application granted granted Critical
Publication of JP7110232B2 publication Critical patent/JP7110232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019556703A 2017-04-18 2018-04-11 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物 Active JP7110232B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022115300A JP7331212B2 (ja) 2017-04-18 2022-07-20 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382207.3 2017-04-18
EP17382207 2017-04-18
PCT/US2018/027005 WO2018194885A1 (en) 2017-04-18 2018-04-11 Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022115300A Division JP7331212B2 (ja) 2017-04-18 2022-07-20 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物

Publications (2)

Publication Number Publication Date
JP2021517555A JP2021517555A (ja) 2021-07-26
JP7110232B2 true JP7110232B2 (ja) 2022-08-01

Family

ID=58606227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556703A Active JP7110232B2 (ja) 2017-04-18 2018-04-11 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
JP2022115300A Active JP7331212B2 (ja) 2017-04-18 2022-07-20 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022115300A Active JP7331212B2 (ja) 2017-04-18 2022-07-20 フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物

Country Status (30)

Country Link
US (2) US11655214B2 (enExample)
EP (2) EP3612519B1 (enExample)
JP (2) JP7110232B2 (enExample)
KR (2) KR20230129627A (enExample)
CN (2) CN110831927B (enExample)
AU (2) AU2018255191B2 (enExample)
BR (1) BR112019021867A2 (enExample)
CO (1) CO2019012767A2 (enExample)
CR (1) CR20190519A (enExample)
CY (1) CY1125150T1 (enExample)
DK (2) DK3612519T3 (enExample)
ES (2) ES2906847T3 (enExample)
FI (1) FI4039675T3 (enExample)
HR (2) HRP20241188T1 (enExample)
HU (2) HUE068023T2 (enExample)
IL (2) IL270005B (enExample)
LT (2) LT3612519T (enExample)
MX (2) MX389724B (enExample)
MY (1) MY199442A (enExample)
NZ (1) NZ758291A (enExample)
PH (1) PH12019502363B1 (enExample)
PL (2) PL3612519T3 (enExample)
PT (2) PT3612519T (enExample)
RS (2) RS65914B1 (enExample)
SA (1) SA519410320B1 (enExample)
SG (1) SG11201909680UA (enExample)
SI (2) SI4039675T1 (enExample)
SM (2) SMT202400357T1 (enExample)
WO (1) WO2018194885A1 (enExample)
ZA (1) ZA201906811B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909680UA (en) * 2017-04-18 2019-11-28 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CN112166187B (zh) 2018-03-26 2025-06-20 西奈山伊坎医学院 治疗微小残留癌的方法
JP2022546410A (ja) * 2019-08-29 2022-11-04 ヒベルセル， インコーポレイテッド Ｐｅｒｋ阻害化合物
US12331054B2 (en) 2019-08-29 2025-06-17 Hibercell, Inc. Perk inhibiting imidazolopyrazine compounds
KR20220066290A (ko) * 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
WO2021041976A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting indolinyl compounds
WO2021231782A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibitors for treating viral infections
WO2021231788A1 (en) * 2020-05-13 2021-11-18 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds to treat viral infections
CN113234029B (zh) * 2021-05-25 2022-03-22 白银康寓信生物科技有限公司 一种2-氨基-3,5-二卤代吡嗪的合成方法
WO2024206890A1 (en) * 2023-03-30 2024-10-03 Hibercell, Inc. Crystalline forms of (r)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-n-isopropylnicotinamide and methods for using the same
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524631A (ja) 2002-01-25 2005-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なインダゾール化合物
JP2005530760A (ja) 2002-05-03 2005-10-13 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
JP2009506979A (ja) 2005-09-02 2009-02-19 アステラス製薬株式会社 新規化合物
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2017019442A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
EP0970084B1 (en) 1997-03-19 2003-06-04 Basf Aktiengesellschaft Pyrrolo 2,3d]pyrimidines and their use as tyrosine kinase inhibitors
NZ544920A (en) * 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CA2716826C (en) 2008-02-25 2017-05-09 Prometheus Laboratories Inc. Drug selection for breast cancer therapy using antibody-based arrays
US20120014911A1 (en) 2009-01-09 2012-01-19 Serge Fuchs Regulators of the Interferon-Alpha Receptor 1 (IFNAR1) Chain of the Interferon Receptor
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
WO2014170706A1 (en) 2013-04-15 2014-10-23 Università Degli Studi Di Bari Galloyl benzamide-based compounds as jnk modulators
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
EA039885B1 (ru) 2014-11-14 2022-03-23 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
KR102327917B1 (ko) 2016-07-07 2021-11-17 주식회사 대웅제약 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
US20190241573A1 (en) 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN106748989B (zh) 2016-11-14 2020-03-17 西安交通大学 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用
EP3573608A1 (en) 2017-01-30 2019-12-04 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
SG11201909680UA (en) 2017-04-18 2019-11-28 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
US11673891B2 (en) 2017-11-14 2023-06-13 Dana-Farber Cancer Institute, Inc. Imidazopyrimidine compounds and uses thereof
EP3492454A1 (en) 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
CN112166187B (zh) 2018-03-26 2025-06-20 西奈山伊坎医学院 治疗微小残留癌的方法
CA3104398A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524631A (ja) 2002-01-25 2005-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なインダゾール化合物
JP2005530760A (ja) 2002-05-03 2005-10-13 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
JP2009506979A (ja) 2005-09-02 2009-02-19 アステラス製薬株式会社 新規化合物
WO2015136463A1 (en) 2014-03-11 2015-09-17 Glaxosmithkline Intellectual Property (No.2) Limited Chemical compounds acting as perk inhibitors
WO2017019442A1 (en) 2015-07-24 2017-02-02 Blueprint Medicines Corporation Compounds useful for treating disorders related to kit and pdgfr

Also Published As

Publication number Publication date
DK4039675T3 (da) 2024-09-02
CN110831927A (zh) 2020-02-21
SI3612519T1 (sl) 2022-04-29
ZA201906811B (en) 2021-01-27
MX2019012428A (es) 2022-01-28
CN110831927B (zh) 2023-07-14
RU2019136694A (ru) 2021-05-18
SI4039675T1 (sl) 2024-10-30
MX389724B (es) 2025-03-20
JP7331212B2 (ja) 2023-08-22
JP2022141835A (ja) 2022-09-29
HUE057745T2 (hu) 2022-06-28
PL4039675T3 (pl) 2025-01-07
EP3612519A1 (en) 2020-02-26
IL288822A (en) 2022-02-01
JP2021517555A (ja) 2021-07-26
CO2019012767A2 (es) 2020-04-01
LT3612519T (lt) 2022-03-25
SMT202200100T1 (it) 2022-03-21
RS65914B1 (sr) 2024-10-31
WO2018194885A1 (en) 2018-10-25
IL270005B (en) 2022-01-01
DK3612519T3 (da) 2022-03-07
NZ758291A (en) 2025-11-28
EP4039675B1 (en) 2024-06-12
MX2022001310A (es) 2022-03-02
CR20190519A (es) 2020-03-06
EP4039675A1 (en) 2022-08-10
HRP20241188T1 (hr) 2024-12-06
ES2988739T3 (es) 2024-11-21
LT4039675T (lt) 2024-10-10
EP3612519B1 (en) 2021-12-01
FI4039675T3 (fi) 2024-09-10
KR20230129627A (ko) 2023-09-08
AU2022206702B2 (en) 2024-04-11
CA3060564A1 (en) 2018-10-25
PT3612519T (pt) 2022-02-22
MY199442A (en) 2023-10-28
SMT202400357T1 (it) 2024-11-15
PL3612519T3 (pl) 2022-05-02
US20210114985A1 (en) 2021-04-22
CY1125150T1 (el) 2023-06-09
KR20190140966A (ko) 2019-12-20
SA519410320B1 (ar) 2022-05-08
PH12019502363A1 (en) 2020-12-07
US20230373922A1 (en) 2023-11-23
HUE068023T2 (hu) 2024-12-28
BR112019021867A2 (pt) 2020-05-26
KR102575246B1 (ko) 2023-09-06
PT4039675T (pt) 2024-09-16
CN117510405A (zh) 2024-02-06
AU2018255191A1 (en) 2019-11-07
AU2022206702A1 (en) 2022-08-11
HRP20220263T1 (hr) 2022-04-29
ES2906847T3 (es) 2022-04-20
PH12019502363B1 (en) 2023-11-15
IL288822B2 (en) 2023-06-01
RS62933B1 (sr) 2022-03-31
AU2018255191B2 (en) 2022-04-21
RU2019136694A3 (enExample) 2021-05-19
SG11201909680UA (en) 2019-11-28
US11655214B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
JP7331212B2 (ja) フェニル－２－ヒドロキシ－アセチルアミノ－２－メチル－フェニル化合物
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
CN114846005B (zh) Shp2抑制剂及其应用
CN105732615A (zh) Cdk激酶抑制剂
JP2022502438A (ja) Ｆｇｆｒ４阻害剤及びその使用
KR20250030448A (ko) Pi3k 억제제로서의 벤조피리미딘-4(3h)-온
RU2804280C2 (ru) Фенил-2-гидрокси-ацетиламино-2-метил-фениловые соединения
CN111039941B (zh) 一种含氮杂环化合物、其制备方法及应用
CA3060564C (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40079392A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
HK40079392B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2017049711A1 (zh) 喹啉类衍生物、其药物组合物、制备方法及应用
HK40024453B (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
TWI692476B (zh) 環丁基-咪唑啶酮化合物
HK40024453A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물
CN106336412A (zh) 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CN117384135A (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN113354630A (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20191226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250